{"id":623460,"date":"2022-11-02T15:16:01","date_gmt":"2022-11-02T15:16:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=623460"},"modified":"2022-11-02T15:16:01","modified_gmt":"2022-11-02T15:16:01","slug":"car-tcell-therapy-competitive-landscape-report-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/car-tcell-therapy-competitive-landscape-report-by-delveinsight_623460.html","title":{"rendered":"CAR T-Cell Therapy Competitive landscape report by DelveInsight"},"content":{"rendered":"
\n
\"CAR<\/a><\/div>\n
\n
CAR T-Cell Therapy Competitive landscape<\/div>\n<\/div>\n<\/div>\n

CAR T-Cell Therapy pipeline constitutes 193+ key companies continuously working towards developing 450+ CAR T-Cell Therapy treatment therapies, analyzes DelveInsight<\/em><\/strong><\/p>\n

A type of treatment in which a patient’s T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein on the patient’s cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion. CAR T-cell therapy is used to treat certain blood cancers, and it is being studied in the treatment of other types of cancer. Also called chimeric antigen receptor T-cell therapy.<\/p>\n

 <\/p>\n

DelveInsights, “CAR T-Cell Therapy Competitive landscape, 2022<\/a>”<\/strong> report provides comprehensive insights about 193+ companies and CAR T – Cell Therapy drugs in CAR T – Cell Therapy Competitive landscape. It covers the therapeutics assessment by product type,stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n

 <\/p>\n

To know more about the CAR T-Cell Therapy pipeline analysis report, click here: CAR T-Cell Therapy Competitive landscape<\/a><\/em><\/strong><\/p>\n

 <\/p>\n

Key Takeaways from the CAR T – Cell Therapy Competitive landscape report:<\/strong><\/p>\n